{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:33:09Z","timestamp":1786116789706,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016308","name":"Public Investment Bank France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-11-INBS-0008"],"award-info":[{"award-number":["ANR-11-INBS-0008"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-10-LABX-77-01"],"award-info":[{"award-number":["ANR-10-LABX-77-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003990","name":"Conseil R\u00e9gional, \u00cele-de-France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007492","name":"Fondation Bettencourt Schueller","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018707","name":"European Commission Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ebiom.2026.106361","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:29:38Z","timestamp":1782941378000},"page":"106361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-0171","authenticated-orcid":false,"given":"Romain","family":"Marlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7616-9775","authenticated-orcid":false,"given":"Mireille","family":"Centlivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Bossevot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Gallou\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3557-7075","authenticated-orcid":false,"given":"Marie","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Planas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8468-0263","authenticated-orcid":false,"given":"Mariangela","family":"Cavarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Staropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Surenaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Cardinaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Galhaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Zurawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Magneron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Pintore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"H\u00e9rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Rameix Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mazet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Relouzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Dereuddre-Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Prague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Zurawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Godot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Le Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5549-6256","authenticated-orcid":false,"given":"Yves","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ebiom.2026.106361_bib1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.ebiom.2026.106361_bib2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMc2302462","article-title":"Durability of bivalent boosters against omicron subvariants","volume":"388","author":"Lin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106361_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jconrel.2024.01.017","article-title":"Protein subunit vaccines: promising frontiers against COVID-19","volume":"366","author":"Chavda","year":"2024","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106361_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2026.106361_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.927306","article-title":"A comprehensive review of the protein subunit vaccines against COVID-19","volume":"13","author":"Heidary","year":"2022","journal-title":"Front Microbiol"},{"issue":"17","key":"10.1016\/j.ebiom.2026.106361_bib6","doi-asserted-by":"crossref","first-page":"7131","DOI":"10.1073\/pnas.1103869108","article-title":"Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates","volume":"108","author":"Flynn","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106361_bib7","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1073\/pnas.0711976105","article-title":"The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine","volume":"105","author":"Trumpfheller","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.20052005","article-title":"Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine","volume":"203","author":"Trumpfheller","year":"2006","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106361_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.smim.2011.02.001","article-title":"Harnessing dendritic cells for immunotherapy","volume":"23","author":"Delamarre","year":"2011","journal-title":"Semin Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib10","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.4049\/jimmunol.182.3.1260","article-title":"Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy","volume":"182","author":"Dickgreber","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.6","article-title":"Targeting dendritic cells: a promising strategy to improve vaccine effectiveness","volume":"5","author":"Macri","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106361_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd3930","article-title":"Clinical targeting of the TNF and TNFR superfamilies","volume":"12","author":"Croft","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ebiom.2026.106361_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ebiom.2016.01.029","article-title":"Functional specialty of CD40 and dendritic cell surface lectins for exogenous antigen presentation to CD8(+) and CD4(+) T cells","volume":"5","author":"Yin","year":"2016","journal-title":"EBioMedicine"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106361_bib14","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1097\/QAD.0b013e3283624305","article-title":"Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells","volume":"27","author":"Flamar","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2026.106361_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102845","article-title":"Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)","volume":"77","author":"Levy","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ebiom.2026.106361_bib16","series-title":"Preliminary Results of a Multicentric Randomized Phase I\/IIa Trial of an Immunotherapy Targeting Dendritic Cells (DC), CD40HVac, in Patients with HPV16-Positive Oropharyngeal Carcinoma (OPC) - 157P. ESMO Immuno-Oncology Congress 2024","author":"Even AW","year":"2024"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106361_bib17","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1038\/s41467-021-25382-0","article-title":"Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques","volume":"12","author":"Marlin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2026.106361_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104062","article-title":"Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine","volume":"80","author":"Coleon","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2026.106361_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105479","article-title":"Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8(+) T cells","volume":"111","author":"Nguema","year":"2025","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106361_bib20","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.4049\/jimmunol.2000704","article-title":"Anti-CD40 antibodies fused to CD40 ligand have superagonist properties","volume":"207","author":"Ceglia","year":"2021","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106361_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207794","article-title":"HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: a comparative study of prototype dendritic cell targeting therapeutic vaccine candidates","volume":"13","author":"Flamar","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106361_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01596-16","article-title":"Superiority in rhesus macaques of targeting HIV-1 env gp140 to CD40 versus LOX-1 in combination with replication-competent NYVAC-KC for induction of env-specific antibody and T cell responses","volume":"91","author":"Zurawski","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2026.106361_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104572","article-title":"Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2","volume":"130","author":"Johnson","year":"2020","journal-title":"J Clin Virol"},{"issue":"7809","key":"10.1016\/j.ebiom.2026.106361_bib24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"Wolfel","year":"2020","journal-title":"Nature"},{"issue":"7871","key":"10.1016\/j.ebiom.2026.106361_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106361_bib26","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","article-title":"Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion","volume":"15","author":"Planas","year":"2024","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106361_bib27","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106267","article-title":"Syncytia formation by SARS-CoV-2-infected cells","volume":"39","author":"Buchrieser","year":"2020","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106361_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib29","article-title":"A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease","volume":"5","author":"Pastor","year":"2024","journal-title":"Cell Rep Med"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106361_bib30","article-title":"Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity","volume":"5","author":"Roederer","year":"2024","journal-title":"Cell Rep Med"},{"issue":"6117","key":"10.1016\/j.ebiom.2026.106361_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/327059a0","article-title":"Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC","volume":"327","author":"Carayanniotis","year":"1987","journal-title":"Nature"},{"issue":"44","key":"10.1016\/j.ebiom.2026.106361_bib32","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116147118","article-title":"A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants","volume":"118","author":"Pishesha","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2026.106361_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41541-019-0101-0","article-title":"Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules","volume":"4","author":"Andersen","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106361_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112391","article-title":"Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses","volume":"42","author":"Kassardjian","year":"2023","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106361_bib35","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20021598","article-title":"Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance","volume":"196","author":"Bonifaz","year":"2002","journal-title":"J Exp Med"},{"issue":"10275","key":"10.1016\/j.ebiom.2026.106361_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106361_bib37","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106361_bib38","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"issue":"7857","key":"10.1016\/j.ebiom.2026.106361_bib40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106361_bib41","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106361_bib42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41541-022-00479-9","article-title":"Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism","volume":"7","author":"Bachmann","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ebiom.2026.106361_bib43","author":"Andrew Rambaut"},{"issue":"7854","key":"10.1016\/j.ebiom.2026.106361_bib44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106361_bib45","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.chom.2021.06.006","article-title":"SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity","volume":"29","author":"Motozono","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib46","article-title":"Deep mutational scanning to predict escape from bebtelovimab in SARS-CoV-2 omicron subvariants","volume":"11","author":"Alcantara","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106361_bib47","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1038\/s41598-021-83761-5","article-title":"Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2","volume":"11","author":"Singh","year":"2021","journal-title":"Sci Rep"},{"issue":"7923","key":"10.1016\/j.ebiom.2026.106361_bib48","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.ebiom.2026.106361_bib49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"695","key":"10.1016\/j.ebiom.2026.106361_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7404","article-title":"Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine","volume":"15","author":"Feng","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2026.106361_bib52","article-title":"Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study","volume":"379","author":"Ferdinands","year":"2022","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106361_bib53","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"10318","key":"10.1016\/j.ebiom.2026.106361_bib54","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib55","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"7890","key":"10.1016\/j.ebiom.2026.106361_bib56","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination","volume":"600","author":"Pozzetto","year":"2021","journal-title":"Nature"},{"issue":"10319","key":"10.1016\/j.ebiom.2026.106361_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"Lancet"},{"issue":"6576","key":"10.1016\/j.ebiom.2026.106361_bib58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106361_bib59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41577-020-00460-4","article-title":"Cross-reactive memory T cells and herd immunity to SARS-CoV-2","volume":"20","author":"Lipsitch","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2026.106361_bib60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","article-title":"T cell responses to SARS-CoV-2","volume":"41","author":"Sette","year":"2023","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106361_bib61","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41423-021-00743-3","article-title":"SARS-CoV-2-specific T cells in infection and vaccination","volume":"18","author":"Bertoletti","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106361_bib62","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1172\/JCI99005","article-title":"TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs","volume":"128","author":"Cheng","year":"2018","journal-title":"J Clin Invest"},{"issue":"770","key":"10.1016\/j.ebiom.2026.106361_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp8920","article-title":"SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity","volume":"16","author":"Lasrado","year":"2024","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106361_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.05163-22","article-title":"Vaccination and Omicron BA.1\/BA.2 convalescence enhance systemic but not mucosal immunity against BA.4\/5","volume":"11","author":"Diem","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"76","key":"10.1016\/j.ebiom.2026.106361_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci Immunol"},{"issue":"770","key":"10.1016\/j.ebiom.2026.106361_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn2364","article-title":"Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa","volume":"16","author":"Declercq","year":"2024","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106361_bib67","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.medj.2022.09.010","article-title":"Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection","volume":"3","author":"Planas","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.ebiom.2026.106361_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104893","article-title":"SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses","volume":"98","author":"Puhach","year":"2023","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106361_bib69","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41590-024-01951-5","article-title":"Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates","volume":"25","author":"Gagne","year":"2024","journal-title":"Nat Immunol"},{"issue":"6561","key":"10.1016\/j.ebiom.2026.106361_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2026.106361_bib71","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.75427","article-title":"Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection","volume":"11","author":"Alexandre","year":"2022","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106361_bib72","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-16-0128","article-title":"Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity","volume":"4","author":"Yin","year":"2016","journal-title":"Cancer Immunol Res"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:20:01Z","timestamp":1786018801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426002446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":72,"alternative-id":["S2352396426002446"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106361","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106361"}}